Intellia Therapeutics Inc (NTLA)
NASDAQ:NTLA
Want to see NTLA full AI Analyst Report?
Top Page
Intellia Therapeutics
(NASDAQ:NTLA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$12.00
▼(-19.73% Downside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weak financial performance (large ongoing losses and cash burn). Offsetting this are a moderately positive earnings-call setup with meaningful clinical/regulatory milestones ahead, while technicals and valuation are neutral-to-middling and do not provide strong support.
Positive Factors
Low leverage and balance-sheet flexibility
Intellia's low leverage and conservative debt profile provide durable financial optionality to fund multi-year clinical programs and commercial prep. This reduces near-term bankruptcy risk and gives management leeway to time non-dilutive partnerships or structured financing instead of urgent fire-sale funding.
Negative Factors
Large, persistent cash burn
Sustained negative operating and free cash flow forces reliance on external funding or collaborations over multi-year timelines. That reliance constrains flexibility, can delay development or commercialization if markets tighten, and increases the probability of future equity raises or partnership concessions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and balance-sheet flexibility
Intellia's low leverage and conservative debt profile provide durable financial optionality to fund multi-year clinical programs and commercial prep. This reduces near-term bankruptcy risk and gives management leeway to time non-dilutive partnerships or structured financing instead of urgent fire-sale funding.
Read all positive factors
Intellia Therapeutics (NTLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.89B
Dividend YieldN/A
Average Volume (3M)8.09M
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth45.04%
EPS Growth32.42%
CountryUS
Employees403
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.54
Shares Outstanding139,722,270
10 Day Avg. Volume5,112,450
30 Day Avg. Volume8,088,799
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue23.07
Enterprise Value/Gross Profit-72.34
Enterprise Value/Ebitda-3.83
Forecast
1Y Price Target
$21.06Price Target Upside40.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$59.62M
Intellia Therapeutics Business Overview & Revenue Model
Company Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 f...
How the Company Makes Money
Intellia Therapeutics has historically generated revenue primarily from collaboration and license arrangements rather than from product sales, because it is a clinical-stage company without widely commercialized therapies. Key revenue streams incl...
Intellia Therapeutics Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.Positive Updates
Lonvo-z Phase 3 Enrollment and Imminent Readout
Completed enrollment of the HAELO Phase 3 trial with 80 patients in ~9 months; top-line data expected by mid-2026 and a planned BLA submission in H2 2026 — positioning Intellia for the world’s first pivotal readout for an in vivo CRISPR gene-editing therapy.
Negative Updates
Clinical Hold on MAGNITUDE (Cardiomyopathy) Remains
MAGNITUDE (ATTR-CM) remains on clinical hold after elevated liver transaminases and total bilirubin observed in a patient; while the company is actively engaged with the FDA and has proposed mitigations, the hold has not yet been lifted, creating uncertainty for a large cardimyopathy cohort that had already enrolled >650 patients (vs ~550 expected).
Read all updates
Q4-2025 Updates
Positive
Negative
Lonvo-z Phase 3 Enrollment and Imminent Readout
Completed enrollment of the HAELO Phase 3 trial with 80 patients in ~9 months; top-line data expected by mid-2026 and a planned BLA submission in H2 2026 — positioning Intellia for the world’s first pivotal readout for an in vivo CRISPR gene-editing therapy.
Read all positive updates
Company Guidance
Management reiterated guidance for a big 2026 year: top‑line phase 3 lonvo‑z data by mid‑2026, a planned BLA submission in H2‑2026 and a potential launch in 2027; HAELO is fully enrolled (80 patients) and pooled data show 76% of patients ≥1 year post‑50 mg were attack‑free ≥12 months (versus ~20% attack‑free on current therapies), while market research (104 patients, 151 HCPs) showed 99% of patients would be at least somewhat likely to take lonvo‑z, 92% of HCPs could identify a patient, and physicians collectively manage ~4,000 patients (~60% of the U.S. treated population) and would prescribe to ~2,200 (54%). For ATTR, MAGNITUDE had >650 patients enrolled before the October hold, MAGNITUDE‑2 has 47 enrolled with a revised target of ~60 and is expected to complete enrollment in H2‑2026 after the FDA lifted the MAGNITUDE‑2 hold in late January; mitigation measures (extra LFT monitoring and short‑term steroid regimens) were agreed given a Grade‑4 LFT incidence of <1%. Financially, cash, cash equivalents and marketable securities were $605.1M at 12/31/25 (down from $861.7M a year earlier) with runway into H2‑2027, Q4 collaboration revenue was $23M, R&D was $88.7M (stock‑based comp $10.5M), G&A $33.1M (stock‑based comp $6.2M) and Q4 net loss was $95.8M (vs $128.9M prior year).Intellia Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.09M | 67.67M | 57.88M | 36.27M | 52.12M | 33.05M |
| Gross Profit | -21.07M | 51.75M | 47.59M | 27.30M | 44.55M | 26.16M |
| EBITDA | -397.65M | -396.77M | -523.98M | -506.31M | -450.59M | -260.96M |
| Net Income | -394.60M | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M |
Balance Sheet | ||||||
| Total Assets | 758.78M | 842.13M | 1.19B | 1.30B | 1.52B | 1.29B |
| Cash, Cash Equivalents and Short-Term Investments | 375.99M | 449.88M | 601.51M | 912.22M | 1.19B | 748.69M |
| Total Debt | 80.49M | 93.33M | 210.20M | 115.35M | 130.70M | 74.02M |
| Total Liabilities | 137.84M | 170.73M | 319.06M | 250.81M | 284.53M | 254.22M |
| Stockholders Equity | 620.94M | 671.39M | 871.96M | 1.05B | 1.24B | 1.04B |
Cash Flow | ||||||
| Free Cash Flow | -363.63M | -354.66M | -354.66M | -408.07M | -391.68M | -237.79M |
| Operating Cash Flow | -363.15M | -348.88M | -348.88M | -394.09M | -333.29M | -225.03M |
| Investing Cash Flow | 200.01M | 125.57M | 125.57M | -31.35M | 160.31M | -550.78M |
| Financing Cash Flow | 165.06M | 185.75M | 185.75M | 130.32M | 582.96M | 736.69M |
Intellia Therapeutics Technical Analysis
Positive
14.95
Price Trends
13.63
Negative
13.38
Positive
13.35
Positive
Market Momentum
0.02
Negative
50.38
Neutral
55.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 14.95 is above the 20-day moving average (MA) of 13.37, above the 50-day MA of 13.63, and above the 200-day MA of 13.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 55.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.
Intellia Therapeutics Risk Analysis
Intellia Therapeutics disclosed 1 risk factors in its most recent earnings report. Intellia Therapeutics reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Governance Q4, 2025
Intellia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.31B | ― | -35.89% | ― | ― | -63.41% | |
56 Neutral | $1.72B | ― | -14.86% | ― | 242.66% | 15.53% | |
52 Neutral | $1.89B | ― | -57.27% | ― | 45.04% | 32.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $778.55M | ― | -141.95% | ― | 5.37% | -60.20% | |
47 Neutral | $814.75M | -7.31 | -11.85% | ― | 47.10% | -35.51% | |
45 Neutral | $367.38M | -5.58 | -39.75% | ― | -100.00% | -2.72% |
* Healthcare Sector Average
NTLA
Intellia Therapeutics
13.54
5.26
63.53%
KURA
Kura Oncology
8.74
2.01
29.87%
CMPX
Compass Therapeutics
2.04
-0.53
-20.62%
ABCL
AbCellera Biologics
5.62
3.11
123.90%
JANX
Janux Therapeutics Inc
13.36
-12.58
-48.50%
BCAX
Bicara Therapeutics Inc.
20.00
8.52
74.22%
Intellia Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline
Positive
Apr 30, 2026
On April 28, 2026, Intellia Therapeutics entered into an underwriting agreement with Jefferies, Goldman Sachs, and Citigroup for a public offering of 16,744,187 common shares at $10.75 per share, plus a 30-day option for 2,511,628 additional share...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intellia Reports Positive Phase 3 Results for HAE Gene Therapy
Positive
Apr 27, 2026
On April 27, 2026, Intellia Therapeutics reported positive topline Phase 3 results from its global HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR-based, one-time gene-editing therapy for hereditary angioedema. The randomized, double-blind...
Business Operations and StrategyRegulatory Filings and Compliance
Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws
Positive
Apr 10, 2026
On April 7, 2026, Intellia Therapeutics, Inc.’s board of directors adopted amendments to its by-laws to create a Fourth Amended and Restated By-law framework, following a recommendation from its nominating and corporate governance committee....
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Intellia Resumes Key Trial and Expands ATM Program
Positive
Mar 2, 2026
On March 2, 2026, Intellia Therapeutics, Inc. amended its at-the-market equity offering agreement with Jefferies LLC, raising the total program size from $750 million to about $1.04 billion and filing a new prospectus supplement to cover up to $40...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.